• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Preclinical development of HIvax: human survivin Highly Immunogenic vaccines

Preclinical development of HIvax: human survivin Highly Immunogenic vaccines

by Adam | Oct 22, 2016

Recent Posts

  • The Platinum Standard Vaccine
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?
  • Tregs as Medicine: Tolerance and InTolerance Seminar

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline